aleglitazar
Small moleculeexperimental
Aleglitazar is a peroxisome proliferator-activated receptor agonist with affinity to PPARα and PPARγ, which was under development by Hoffmann–La Roche for the treatment of type II diabetes. It is no longer in phase III clinical trials. — Wikipedia
Clinical trial activity
22 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
14
Phase 3
8
Phase 4
0
Earliest trial started Nov 1, 2006 (NCT00388518)
Timeline
Indications
Mechanism of action
PPARA agonist
Development stopped due to safety concerns and lack of efficacy (http://www.roche.com/media/media_releases/med-cor-2013-07-10.htm)
PPARG agonist
Development stopped due to safety concerns and lack of efficacy (http://www.roche.com/media/media_releases/med-cor-2013-07-10.htm)
Chemistry & pharmacology
Loading structure…
SMILES
CO[C@@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccsc12)C(=O)O- Mol. weight
- 437.52 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAleglitazar ↗
- ChEMBLCHEMBL519504 ↗
Also known as
- aleglitazar
- aleglitazar
- aleglitazar
- aleglitazar
- r-1439
- r-1439
- ro-0728804
- ro-0728804
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01893242 | Phase 3 | Dec 1, 2013 | Roche |
| NCT01871428 | Phase 3 | Jun 1, 2013 | Roche |
| NCT01871415 | Phase 3 | May 1, 2013 | Roche |
| NCT01691989 | Phase 3 | Dec 1, 2012 | Roche |
| NCT01729403 | Phase 2 | Dec 1, 2012 | Roche |
| NCT01715818 | Phase 3 | Dec 1, 2012 | Roche |
| NCT01711775 | Phase 1 | Nov 1, 2012 | Roche |
| NCT01691755 | Phase 3 | Nov 1, 2012 | Roche |
| NCT01680978 | Phase 2 | Oct 1, 2012 | Roche |
| NCT01691846 | Phase 3 | Oct 1, 2012 | Roche |
| NCT01701739 | Phase 1 | Oct 1, 2012 | Roche |
| NCT01679639 | Phase 1 | Aug 1, 2012 | Roche |
| NCT01615354 | Phase 1 | Jul 1, 2012 | Roche |
| NCT01398267 | Phase 1 | Aug 1, 2011 | Roche |
| NCT01197911 | Phase 1 | Sep 1, 2010 | Roche |
| NCT01188304 | Phase 1 | Jul 1, 2010 | Roche |
| NCT01188317 | Phase 1 | Jun 1, 2010 | Roche |
| NCT01043029 | Phase 2 | May 1, 2010 | Roche |
| NCT01042769 | Phase 3 | Feb 1, 2010 | Roche |
| NCT00461006 | Phase 2 | Jun 1, 2007 | Roche |
Showing 20 of 22 trials
Page 1 / 2
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 22 | 22 | 3 | 2006 |
1 organizations
Page 1 / 1